



Fig. S6 OS of PAN Cancer cohort patients with a 'high E2F1/high APLF/high DCLRE1C' tumor signature (red) versus patients without this signature. There is no significant change in survival probability relative to 'high E2F1/low APLF/low DCLRE1C' (black), 'high E2F1/high APLF/low DCLRE1C' (blue), or 'high E2F1/low APLF/high DCLRE1C' (yellow) tumor signatures.